Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(3):245-259
There is a clinical need for newer effective antimicrobials that would overcome resistance mechanisms across a wide range of microorganisms. Doripenem is a novel promising carbapenem antimicrobial, which was approved by Food and Drug Administration in October, 2007. It is expected to be approved in Russia in 2008. Doripenem has a broad spectrum of activity against Gram-positive, Gram-negative (including multiresistant strains), and anaerobic bacteria. Compared to other antipseudomonal antimicrobials (imipenem and meropenem), doripenem has higher in vitro activity against some of Gram-negative microorganisms (including P. aeruginosa). Clinical trials have demonstrated that doripenem was effective and well tolerated agent in patients with complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), urinary tract infections (UTI) as well as hospital-acquired pneumonia (including ventilator-associated pneumonia). Efficacy and safety of doripenem are also being evaluated in other infections caused by P. aeruginosa.